|
1) Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol. 2005; 29: 1356-66
|
|
|
|
2) Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995; 151: 527-33
|
|
|
|
|
|
3) McCormack FX, Sullivan EJ, Inoue Y. Lymph-angioleiomyomatosis. In: Mason RJ, Broaddus VC, MartinTR, et al. editors. Murray&Nadel's textbook of respiratory medicine. Philadelphia: Saunders Elsevier. 2010; p.1496-515
|
|
|
|
|
|
4) Lautenbacher R. Dysembriomes metotipiques des reins, carcinose submiliereaigue puomon avec amphyseme generalize et double pneumothorax. Ann Med Interne (Paris). 1918; 5: 435-50
|
|
|
|
|
|
5) Cornog JL Jr, Enterline HT. Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer. 1966; 19: 1909-30
|
|
|
|
|
|
6) Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 140-51
|
|
|
|
|
|
7) Johnson SR, Cordier JF, Lazor R, et al (ERS task force). European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010; 35: 14-26
|
|
|
|
|
|
8) 山中 晃, 斎木茂樹. びまん性過誤腫性肺脈管筋腫症: 慢性閉塞性肺疾患鑑別のために. 肺と心. 1970; 17: 171-81
|
|
|
|
|
|
9) Hayashida M, Seyama K, Inoue Y, et al. The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross-sectional study of presenting features and prognostic factors. Respirology. 2007; 12: 523-30
|
|
|
|
|
|
10) 林田美江, 久保惠嗣, 瀬山邦明, 他. リンパ脈管筋腫 lymphangioleiomyomatosis(LAM)診断基準. 日呼吸会誌. 2008; 46: 425-427
|
|
|
|
|
11) 林田美江, 藤本圭作, 久保惠嗣, 他. リンパ脈管筋腫 lymphangioleiomyomatosis(LAM)の治療と管理の手引き. 日呼吸会誌. 2008; 46: 428-431
|
|
|
|
|
|
12) 広瀬雅樹, 井上義一. リンパ脈管筋腫症に関する分子生物学的解析. 最新医学. 2010; 65: 146-54
|
|
|
|
|
|
13) Inoue Y, King TE Jr, Barker E, et al. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2002; 166: 765-73
|
|
|
|
|
|
14) Young L, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 199-200
|
|
|
|
|
|
15) Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001; 25: 479-84
|
|
|
|
|
|
16) Silverstein EF, Ellis K, Wolff M, et al. Pulmonary lymphangiomyomatosis. AJR Am J Roentrogenol. 1974; 120: 832-50
|
|
|
|
|
|
17) Corrin B, Liebow AA, Friedman PJ. Pumonary lymphangiomyomatosis. A review. Am J Pathol. 1975; 79: 348-82
|
|
|
|
|
|
18) Taylor JR, Ryu J, Colby TV, et al. Lymphngioleiomyomatosis. Clinical course in 32 patients. N Engl J Med. 1990; 323: 1254-60
|
|
|
|
|
|
19) Chu SC, Horiba K, Usiki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest. 1999; 115: 1041-52
|
|
|
|
|
|
20) 大家晃子, 井上義一. リンパ脈管筋腫症. In: 工藤翔二, 中田紘一郎, 貫和敏博, 編. 呼吸器疾患の最新の治療 2007-2009. 南江堂; 2007. p.318-20
|
|
|
|
|
|
21) Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangioleiomyomatosis: a metaanalysis. Chest. 1989; 196: 1352-5
|
|
|
|
|
|
22) Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006; 173: 105-11
|
|
|
|
|
|
23) Rossi GA, Balbi B, Oddera S, et al. Response to treatment with an analog of the luteinizing-hormonereleasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis. 1991; 143: 174-6
|
|
|
|
|
|
24) Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999; 160: 628-33
|
|
|
|
|
|
25) Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004; 126: 1867-74
|
|
|
|
|